-
10:38:37 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

Trending News

Covid-19 News LIVE

The stock market news feed is automatically updated to show the latest 50 news.
The news is in real time for GOLD users while a 15 second delay is applied for FREE users.

Become a Gold member to unlock the feed filters, voice notification and see the news without delay.

Check out our Stock Market News Today and Join our Discord

08/09/22 8:30 AM
Nasdaq : VERU
clinical trialcovid-19high short
Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 11th International Conference on Emerging Infectious Diseases (ICEID) on August 7-10, 2022
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Phase 3 COVID-19 study
RHEA-AI
neutral
08/09/22 8:00 AM
Nasdaq : HGBL
covid-19
Heritage Global Partners to Conduct State-of-The-Art Lab Equipment Auction From Former Covid-19 Test Site
Heritage Global Partners, a worldwide leader in asset advisory and auction services, and a subsidiary of Heritage Global Inc., opened online bidding today for a state-of-the-art former Covid-19 testing site. David Barkoff, Senior Vice President at HGP commented,“ We are excited to host this fantastic auction event. About HGP Heritage Global Partners, Inc. Is a...
RHEA-AI
neutral
08/04/22 4:02 PM
Nasdaq : AKBA
clinical trialcovid-19
Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with COVID-19 and Hypoxemia (VSTAT)
Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced initial findings from an investigator-sponsored study evaluating vadadustat, Akebia's
RHEA-AI
neutral
08/03/22 9:00 AM
Nasdaq : SRNE
clinical trialcovid-19
Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster
Single ascending dose (SAD) Phase 1 Study completed in Australia with a maximum dose of 2,000 mg. Pharmacokinetics (PK) were dose proportional and PK modeling and preclinical data support a 600 mg twice daily dose. There were no serious AEs (SAEs) or severe TEAEs and the maximum tolerated dose
RHEA-AI
negative
08/03/22 6:00 AM
Nasdaq : SVA
covid-19
SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination for local children and adolescents, the Health Bureau of the Government of the Hong Kong Special Administrative Region of the People’ s Republic of China has approved the Company’ s COVID-19 vaccine,...
RHEA-AI
neutral
08/02/22 6:00 AM
Nasdaq : AXLA
clinical trialcovid-19
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
Additionally, it was stated that Long COVID contributed to approximately $1 trillion in lost earnings and $529 billion in increased medical spending. Given the lack of therapeutic options for Long COVID patients and based on our understanding of AXA1125’ s positive impact on mitochondrial function, bioenergetics, and inflammation, Axcella conducted a...
RHEA-AI
neutral
07/29/22 7:00 AM
Nasdaq : ENTA
clinical trialcovid-19low float
Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced positive topline data from a Phase 1 study assessing the safety, tolerability, and pharmacokinetics of orally administered single ascending doses and multiple ascending doses of...
RHEA-AI
positive
07/28/22 7:00 AM
NYSE : DNA
covid-19
Clinical Enterprise, Inc. and Ginkgo Bioworks to Continue Support of Federal COVID-19 Testing Program Through 2022
Clinical Enterprise, Inc., a member of the Eurofins Clinical Diagnostic group of companies, today announced that it is extending its partnership with Ginkgo Bioworks to continue supporting the Operation Expanded Testing program with the U.S. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, and...
RHEA-AI
neutral
07/27/22 11:00 AM
Nasdaq : VERU
covid-19high short
European Medicines Agency’s Emergency Task Force Has Initiated the Review of Veru's Sabizabulin Treatment for Hospitalized COVID-19 Patients for Emergency Use in European Union Countries
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the European Medicines Agency’s
RHEA-AI
negative
07/26/22 7:00 PM
OTC : BRIBY
covid-19
Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants
Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to dateThe amubarvimab/romlusevimab combination is commercially available in China and is under review
RHEA-AI
neutral
07/25/22 7:30 AM
Nasdaq : VERU
covid-19high short
UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the United Kingdom’s (UK’s)
RHEA-AI
neutral
07/22/22 7:06 AM
Nasdaq : GILD
covid-19
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Commission adopted a positive opinion on the fulfillment of the last specific obligation and recommended the granting of Marketing Authorization for Veklury ® that is no longer subject to specific obligations. The EC will review the CHMP...
RHEA-AI
neutral
07/21/22 4:00 PM
Nasdaq : SRCE
dividendsearningscovid-19low float
1st Source Corporation Reports Second Quarter Results, a Record Quarter Adjusted for PPP Income Due to Government Response to COVID-19; Cash Dividend Increased
1st Source Corporation, parent company of 1st Source Bank, today reported quarterly net income of $29.31 million for the second quarter of 2022, down 3.01% from the $30.22 million reported in the second quarter a year ago, bringing the 2022 year-to-date net income to $56.70 million compared to $58.33 million in 2021. Excluding tax-effected PPP income, net...
RHEA-AI
neutral
07/20/22 8:30 AM
Nasdaq : VXRT
clinical trialcovid-19
Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive
Vaccine-induced mucosal IgA antibody responses persisted for up to 1 year and had a higher neutralizing activity compared with convalescent samples Vaxart will leverage data gained from trial as it develops additional vaccine candidates SOUTH SAN FRANCISCO, Calif., July 20, 2022
RHEA-AI
neutral
07/19/22 12:30 AM
OTC : BRIBY
partnershipcovid-19
Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in ChinaThe amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China, evaluated through a
RHEA-AI
positive
07/18/22 9:00 AM
OTC : TSOI
clinical trialcovid-19
Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell™ Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial
Therapeutic Solutions International announced today granting of Emergency IND# 28685 and a“ May Proceed Notification” from the Food and Drug Administration for the treatment of advanced COVID-19 ARDS outside of the currently ongoing Double Blind Placebo Controlled Phase III clinical trial for the same indication. James Veltmeyer, Chief Medical Officer...
RHEA-AI
neutral